

APPENDIX 1 PLASMA DERIVED PRODUCTS

The batch number of all plasma derived products must be recorded in the patient history

Albumin

Immunoglobulins

http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins

Intravenous Immunoglobulin (IVIg)	CPP0486
Intramuscular Immunoglobulin	For passive immunisation of contacts of people with hepatitis A, measles, poliomyelitis and rubella
Rh D (IM)	To prevent sensitisation of RhD negative women during pregnancy and postnatal. CPP0425 To prevent RhD alloimmunisation in the unlikely event of and RhD incompatible transfusion
Rh D (IV)	In some circumstances access to an intravenous preparation may be warranted
Cytomegalovirus	Prevention or treatment of cytomegalovirus infection in immunocompromised patients
Zoster (IM)	Prevention of chickenpox or shingles in immunocompromised patient exposed to varicella zoster virus
Tetanus (IM)	Prevention of tetanus in tetanus-prone wounds
Tetanus (IV)	Treatment of clinical tetanus
Hepatitis B	Post-exposure prophylaxis for hepatitis B where vaccination has not been given or is incomplete, including infants born to hepatitis B-positive mothers

Factor Concentrates

http://www.transfusion.com.au/blood_products/fractionated_plasma/factor_concentrates

Prothrombinex-VF	DRG0031
Biostat Clotting Factor VII concentrate	For the treatment of Haemophilia A and von Willebrand disorder
MonoFIX-VF Clotting Factor IX concentrate	For the treatment of haemorrhage, use in surgery, and as prophylaxis in patients with Haemophilia B
Thrombotrol- VF Antithrombin III	Indicated in patients with hereditary deficiency of antithrombin III in the following circumstances > prophylactic administration for the prevention of thrombosis and pulmonary embolism in surgery, pregnancy and childbirth > therapeutic administration in thrombosis or pulmonary embolism > acquired deficiencies e.g. liver disease, DIC